Online GLP-1 Programs in New York
New York runs one of the country's largest Medicaid programs and expanded Medicaid, yet it still does not cover GLP-1s for weight loss. A 2025 bill could change that. For now, most New Yorkers access semaglutide and tirzepatide through commercial insurance, cash-pay, or telehealth.
Population
19.8M
4th-largest state
Adult obesity
29.5%
2024 BRFSS
Diagnosed diabetes
12.3%
2024 BRFSS
Medicaid (weight loss)
Not coveredFrom $129/mo · Ships in 2–4 days · Sponsored
Insurance
Does New York Medicaid cover GLP-1s?
Despite running one of the nation's largest Medicaid programs, New York does not cover GLP-1s for obesity. It is not among the 13 states covering the weight-loss indication as of January 2026 (KFF, 2026). A bill introduced in December 2025 (Assembly A9360) would require Medicaid coverage of GLP-1s for obesity but has not been enacted (NY State Assembly, 2025). GLP-1s for type 2 diabetes are covered, as federal law requires.
Online Access
Getting a GLP-1 online in New York
GLP-1s are not controlled substances, so New York permits telehealth prescribing under standard standard-of-care rules. The key requirement is that the prescribing clinician hold a New York license, since licensure follows the patient's location (Center for Connected Health Policy, 2025). Licensed online programs can serve residents across the state.
Compounding
Compounded semaglutide & tirzepatide in New York
Routine compounding of semaglutide and tirzepatide ended after the FDA resolved the shortages in early 2025 (McDermott Will & Emery, 2025). New York adds no special carve-out beyond the federal 503A/503B framework, so compounding is limited to documented, patient-specific clinical need.
Demand
Where GLP-1 demand is highest in New York
New York's adult obesity rate, around 29.5%, is among the lowest in the country, but its sheer size still makes it a major GLP-1 market. The New York City metro anchors demand, with upstate hubs in Buffalo, Rochester, Albany, and Syracuse. Roughly 12% of adults have diagnosed diabetes (BRFSS, 2024), and pending legislation suggests coverage pressure is building.
Questions
New York GLP-1 FAQ
Does New York Medicaid cover Wegovy or Zepbound?
Not for weight loss. New York Medicaid excludes the obesity indication as of 2026, though a pending bill (A9360) would add it. GLP-1s for type 2 diabetes are covered (KFF, 2026; NY State Assembly, 2025).
Can I get a GLP-1 prescription via telehealth in New York?
Yes, provided the prescribing clinician holds a New York license. GLP-1s are not controlled substances, so standard telehealth standard-of-care rules apply.
Is compounded semaglutide available in New York?
Only for documented patient-specific need. Routine compounding ended after the FDA resolved the shortages in 2025, and New York follows the federal framework with no special carve-out.
Compound Guides
The GLP-1s behind these programs
Sources
How we sourced this page
Coverage, prevalence, and policy figures are drawn from primary and authoritative sources, last reviewed June 2026.
- 1.KFF — Medicaid Coverage of and Spending on GLP-1s (Jan 2026)
- 2.NY State Assembly — Bill A9360 (2025-2026)
- 3.America's Health Rankings — New York obesity (CDC BRFSS 2024)
- 4.America's Health Rankings — New York diabetes (CDC BRFSS 2024)
- 5.McDermott Will & Emery — Semaglutide shortage resolved (2025)
- 6.Center for Connected Health Policy — online prescribing
Telehealth, no insurance needed
Personalized GLP-1 for New York residents
Skip the coverage maze. Yucca Health connects New York residents with US-licensed clinicians for personalized GLP-1 treatment, from $129/mo.
See if you qualifySponsored · Affiliate disclosure
Educational information only, not medical or legal advice and not a substitute for a licensed clinician. GLP-1 coverage, telehealth, and compounding rules vary by state and change frequently; verify the current rules for your state before starting treatment. Links to Yucca Health are sponsored. Last reviewed 2026-06-13.